Angelini Fine Chemicals developed a new area to increase the production of HPAPI

Dji 0355 Corretta
  • Published: 24 Feb 2021

Angelini Fine Chemicas is the Business Unit of Angelini Pharma SpA, specialized in the production of active pharmaceutical ingredients (APls) and a leader in ltaly in third-party contract manufacturing (COMO), has increased its focus on the production of high-potent active pharmaceutical ingredients (HPAPls). The company has infact implemented a new area of its plant in Aprilia (LT), in Lazio- ltaly; with the aim of expanding it s HPAPI R&O and manufacturing capacity, strengthening its portfolio for COMO services for its current and fut ure customers.

The new area covers approximately 120 square meters and will allow the management of HPAPI production activities in two different laboratories with batch size 0.25-5+ kg. The expansion of the plant is part of an investment of € 4,000,000 started in 2017. An area dedicated to HPAPI is added to the 3 existing laboratories dedicated to development activities for the COMO and generic API area. The new suite includes two new areas for the separate and simultaneous management of different products.

The global pandemic has not affected the production of active ingredients, especially HPAPI used mainly in drugs and oncological treatments.  According to the latest report from Transparency Market Research (TMR), the global high potent active ingredients (HPAPI) market was valued at $ 17.46 billion in 2018 with CAGR m ore than 8.7 % from 2019 lo 2027.

"High potent active ìngredients wìll become more and more centrai in the world of the pharmaceutical industry, especìally in the post-pandemic period in which, due to Covid-19, cancer screening has been delayed and waiting lists have lengthened - comments Giovanni De Filippo, Fine Chemicals Sales & BD Head - We believe that the expansion of our plant is timely, as it will allow us to increase the number of HPAPI programs and, even more, thanks to a "fully-integratedstrategy we will be able to follow the entire deve!opment of the molecule, from research to industrial production within our factory, optimizing time and resources".

The increasingly important presence of high potent active ingredients and the continuous development of this sector makes it necessary to adapt production sites to ensure maximum safety in the management of molecules. lt is for this reason that Angelini Fine Chemicals, in recent years, has invested in technological platforms of the highest level able to handle these products, with high standards, and to guarantee the maximum safety of its specialists. All laboratories allow the maximum containment of high potent molecules, guaranteeing workers the highest safety standard: an occupational exposure band (OEB5) that does not exceed the exposure limit of 0.1 µg / m3.

The constantly growing company also renovated its offices and chemical research and development laboratories on November 2020 to offer increasingly integrated solutions: starting from the analysis, research and development phase, passing through the scale-up and test phase of production, up to the real industriai production destined to the final markets.